Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.24 USD | -3.25% | +10.39% | +11.19% |
May. 09 | RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk | MT |
May. 08 | Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000 | MT |
Business Summary
Number of employees: 216
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Engineered Immunoglobulin M Antibodies
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +99.25% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +99.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 03-01-31 |
Misbah Tahir
DFI | Director of Finance/CFO | 49 | 18-12-31 |
T. S. Harigopal
COO | Chief Operating Officer | - | 20-12-31 |
Chris Takimoto
CTO | Chief Tech/Sci/R&D Officer | 65 | 21-07-28 |
Bruce Keyt
CTO | Chief Tech/Sci/R&D Officer | 71 | 09-12-31 |
Lisa Wax
LAW | General Counsel | - | 20-12-31 |
Corporate Officer/Principal | - | 17-12-31 | |
George Gauthier
PRN | Corporate Officer/Principal | 52 | 21-04-11 |
Steven Weber
AUD | Comptroller/Controller/Auditor | 48 | 22-02-28 |
Paul Graffagnino
LAW | General Counsel | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 21-01-25 |
M. Wilsey
BRD | Director/Board Member | 71 | 19-01-30 |
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 03-01-31 |
Michael Lee
BRD | Director/Board Member | 45 | 19-06-30 |
Julie Hambleton
BRD | Director/Board Member | 66 | 18-08-14 |
Director/Board Member | 55 | 18-07-31 | |
Director/Board Member | 43 | 18-07-31 | |
William Strohl
BRD | Director/Board Member | 71 | 18-07-31 |
Director/Board Member | 49 | 23-10-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 25,386,983 | 0 | 0 | 37.37 % |
Stock B | 1 | 33,636,592 | 22,059,861 ( 65.58 %) | 0 |
Company contact information
IGM Biosciences, Inc.
325 East Middlefield Road
94043, Mountain View
+650 965 7873
http://www.igmbio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.19% | 564M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- IGMS Stock
- Company IGM Biosciences, Inc.